Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CNS Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: CNS Cancer. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003896-37 Sponsor Protocol Number: ODO-TE-B201 Start Date*: 2019-06-18
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer ...
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000824-21 Sponsor Protocol Number: IJB-NERABRAIN-ODN-007 Start Date*: 2021-10-05
    Sponsor Name:Institut Jules Bordet
    Full Title: An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer
    Medical condition: HER2 positive breast cancer patients with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004239-25 Sponsor Protocol Number: GO42286 Start Date*: 2021-05-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ALECTINIB IN PEDIATRIC PATIENTS WITH ALK FUSION POSITIVE SOLID OR CNS TUMORS FOR WHOM PRIOR TREA...
    Medical condition: ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028992 Neoplasm CNS LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001027-40 Sponsor Protocol Number: ERIBRAIN-IPC2017-014 Start Date*: 2018-09-11
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes
    Medical condition: HER2-negative breast cancer with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005048-46 Sponsor Protocol Number: D9673C00007 Start Date*: 2021-06-02
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive...
    Medical condition: Treatment of patients with HER2-positive breast cancer with or without brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IE (Trial now transitioned) SE (Completed) NO (Completed) BE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) FI (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003859-11 Sponsor Protocol Number: MO41552 Start Date*: 2022-02-03
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WI...
    Medical condition: Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date*: Information not available in EudraCT
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
    Medical condition: Patients with Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001739-29 Sponsor Protocol Number: MedOPP243 Start Date*: 2020-05-25
    Sponsor Name:Medica Scientia Innovation Research S.L. (MEDSIR)
    Full Title: A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer wi...
    Medical condition: Pretreated, unresectable locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive or HER2-low expressing breast cancer (BC) with untreated or treated brain metastases...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000364-30 Sponsor Protocol Number: I4T-MC-JVDA Start Date*: 2021-06-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
    Medical condition: Pediatric Solid Tumor CNS Malignancies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000634-29 Sponsor Protocol Number: MO29750 Start Date*: 2015-08-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREAT...
    Medical condition: Anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) DE (Completed) SK (Completed) HU (Completed) FR (Completed) PL (Completed) BE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001590-68 Sponsor Protocol Number: 03-133 Start Date*: 2020-11-26
    Sponsor Name:Y-mAbs Therapeutics Inc.
    Full Title: Phase I Study Of Intrathecal Radioimmunotherapy Using 131I-Omburtamab for Central Nervous System/Leptomeningeal Neoplasms
    Medical condition: Treatment of pediatric neuroblastoma patients with CNS relapse as evidenced by CNS/LM metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073130 Central nervous system neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000591-97 Sponsor Protocol Number: CLSG-CNS-001 Start Date*: 2015-06-03
    Sponsor Name:Kooperativní lymfomová skupina, o.s.
    Full Title: Study evaluating relapses in central nervous system in patients with diffuse large B-cell lymphoma treated with chemotherapy with or without CNS prophylaxis. Multicentric, prospective randomized p...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000212-28 Sponsor Protocol Number: LOXO-RET-18036 Start Date*: 2020-04-15
    Sponsor Name:Loxo Oncology, Inc.
    Full Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
    Medical condition: Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007959 Central nervous system neoplasm NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049516 Malignant tumor LLT
    20.1 100000004852 10007960 Central nervous system neoplasms malignant NEC HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005194-32 Sponsor Protocol Number: CRANIAL Start Date*: 2013-06-28
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer
    Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059282 Metastases to central nervous system PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001306-33 Sponsor Protocol Number: PQR309-005 Start Date*: 2017-03-08
    Sponsor Name:PIQUR Therapeutics AG
    Full Title: Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma
    Medical condition: Relapsed or refractory primary CNS lymphoma (PCNSL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014722-42 Sponsor Protocol Number: HO105 Start Date*: 2010-07-07
    Sponsor Name:HOVON Foundation
    Full Title: Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study
    Medical condition: Primary Central Nervous system Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-022737-28 Sponsor Protocol Number: CO10/9344 Start Date*: 2011-02-03
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after lo...
    Medical condition: Patients with ERB B2 positive metastatic breast cancer developing brain metastasis/es
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001894-34 Sponsor Protocol Number: E7389-A001-113 Start Date*: 2016-11-16
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1 Study of Eribulin Mesylate (E7389, IND #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lym...
    Medical condition: Solid Tumors including Lymphomas
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004715-41 Sponsor Protocol Number: ODO-TE-B202 Start Date*: 2019-12-24
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 06:57:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA